Nomura Research Institute (4307) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
13 Feb, 2026Executive summary
Revenue for 1Q FY March 2025 rose 6.5% year-over-year to ¥188,110 million, with operating profit up 20.8% to ¥32,643 million and net profit attributable to owners up 28.8% to ¥22,166 million.
Gross profit margin improved to 36.0% from 35.7%, and operating margin increased to 17.4% from 15.3% year-over-year.
Strong domestic demand and improved profitability from DX consulting and financial IT solutions projects, with North America showing financial improvement though overseas demand recovery is expected later in the year.
Financial highlights
EBITDA margin improved to 23.6% from 21.9% year-over-year.
Basic earnings per share rose to ¥38.51 from ¥29.15 year-over-year.
Cash and cash equivalents at period end were ¥154,094 million, up 10.5% year-over-year.
Free cash flow for the quarter was ¥19,670 million, down 28.8% year-over-year.
Outlook and guidance
Full-year FY March 2025 revenue forecast remains at ¥780 billion, with operating profit at ¥132 billion.
Overseas demand recovery is expected in the second half of the year at the earliest.
Annual EPS forecast is ¥152.71, and annual dividend per share is projected at ¥58.00.
Latest events from Nomura Research Institute
- Double-digit profit growth and AI-driven transformation set the stage for FY26 expansion.4307
Q4 202513 Feb 2026 - Strong revenue and profit growth in 1H FY Mar. 2025, with improved margins and robust outlook.4307
Q2 202513 Feb 2026 - Revenue and profit up, guidance and dividend raised on strong Consulting and IT growth.4307
Q3 202513 Feb 2026 - Strong domestic IT and consulting growth drives higher revenue and profit, with overseas reform ongoing.4307
Q3 202629 Jan 2026 - Strong domestic and AI-driven growth boost profits; full-year outlook and dividends raised.4307
Q2 202630 Oct 2025 - Operating profit rose 14.1% year-over-year, driven by strong IT and consulting growth.4307
Q1 202628 Jul 2025